coronary endothelial dysfunction induces myocardial perfusion defects in humans with impaired endothelium-dependent coronary flow reserve 5) . In the presence of endothelial dysfunction, the release of vasodilatory substances, such as nitric oxide (NO), decreases, while the release of endothelin, an endotheliumderived vasoconstrictive peptide, increases and may change vascular tone via interaction with NO. Accordingly, as also suggested in epicardial coronary spasm, coronary microvascular endothelial dysfunction is considered to be involved in the genesis of microvascular spasm 6) . In fact, it has been reported that plasma endothelin-1 (ET-1) in the coronary sinus increases not only during epicardial coronary artery spasm induced by acetylcholine 7) Introduction Coronary microvascular spasm occurs in patients with and without epicardial coronary artery spasm 1) ; however, the mechanism of coronary artery microvascular spasm is still under debate 1, 2) . Hypercontraction of vascular smooth muscle cells and increased neurohumoral substances for inducing coronary microvascular spasm are probable, as pointed out in epicardial coronary artery spasm 3, 4) . Hasdai et al. showed that important role in the genesis of coronary microvascular spasm; however, there are few data showing the relation between the degree of coronary microvascular spasm and levels of ET-1. It has been reported that bosentan (Ro 47-0203), a non-selective endothelin receptor antagonist, is effective for the treatment of primary pulmonary hypertension, based on the hypercontractility of smooth muscle cells of the pulmonary artery 8) . Moreover, if ET-1 is assumed to be primarily related to the cause of coronary microvascular spasm, treatment with an ET-1 antagonist should be highly effective to prevent microvascular spasm.
We have reported using pigs that repeated epicardial coronary artery endothelial injuries followed by regeneration, which may be similar to the situation in endothelial dysfunction or the process of atherosclerosis during a life time, induce coronary microvascular spasm 9, 10) . The purpose of the present study is to clarify the correlation between ET-1 and coronary microvascular spasm as well as the therapeutic efficacy of endothelin type A receptor (ETA) antagonist.
Methods

Study Protocols
Thirty-two domestic pigs (25 0.5 kg) were used in this study. Pigs were initially anesthetized with 10 mg/kg ketamine hydrochloride intramuscularly and 2 mg/kg sodium thiopental intravenously, and then incubated and mechanically ventilated with a respirator. Anesthesia was maintained with 1% to 2% halothane. After a left thoracotomy at the fourth intercostal space, we implanted an ultrasonic transit-time flowmeter (Trasonic T201D; Transonic System Inc, New York) around the epicardial proximal left anterior descending coronary artery (LAD), as previously reported 9, 10) . Pigs were assigned to three experimental groups, i.e., no medication and no epicardial LAD endothelial denudation, described later (Control group, n 12), repeated epicardial LAD endothelial denudation but no medication (ED group, n 10), and chronic treatment with oral TA-0201 0.1 mg/kg/day just after first denudation, an endothelin type A receptor (ETA) selective antagonist, N-(6-(2-(5-bromopyrimidin-2-pyloxy)ethoxy)-5-(4methylphenyl)pyrimidin-4-yl)-4-(2-hydrox y-1,1-dimethylethyl) benzensulfonamide sodium salt sesquihydrate (ED ETA group, n 10). TA-0201 was generously provided by Tanabe Co. (Tokyo, Japan). All experiments using animals were performed according to the guidelines of Fukushima Medical University and the Japanese Government Notification on Feeding and Safekeeping of Animals (NO.6).
Experiments were initiated two weeks after implantation of a flowmeter. After injecting 150 U/kg heparin i.v, we made a control recording of LAD blood flow, electrocardiograms (ECGs) from limbs ( , aVF) and precordial leads (V5), and aortic blood pressure via a 6F sheath introducer using a pressure transducer (AP641G; Nihon Kohden). After making a control recording of the coronary diameter using a 6F Judkins-type angiographic catheter, acetylcholine (ACh) 0.05 g/kg (Ovisot, Daiichi, Tokyo, Japan) was infused over 30 seconds into the left main coronary artery through a Judkins-type catheter, inserted through the sheath introducer. The dose of acetylcholine was selected as similar to those reported previously, and acetylcholine 0.05 g/kg was suitable for observing vascular responses in the microvascular coronary artery throughout the experiment 9) . Coronary angiography was performed when initial changes in coronary blood flow in response to vasoactive agents were maximum. ECG ST-segment shifts were determined 80 ms after the J-point of the QRS complex. Significant ischemic ECG ST changes were defined as more than 0.1 mV ST-segment elevation or sagging and/or horizontal depression continuing for more than 1 mm.
Next, balloon endothelial denudation was performed just distal to the site of the flowmeter in the LAD using a 2F Fogarty catheter, as previously described 9, 10) . Briefly, after balloon inflation, three denudation procedures were performed over 4 cm in the same portion of the artery. Two weeks after denudation, the same protocol as for the examination of coronary and systemic hemodynamics and then the denudation protocol were performed again and repeated every two weeks for a total of four times (0, 2, 4, 6 W). Coronary flow response to ACh was expressed as % change of the peak flow response from the preinjection baseline value, which was nearly constant throughout the experiment 9, 10) .
Determination of TA-0201 dose
We tested three doses of orally administered TA-0201, 0.05, 0.1 and 0.5 mg/kg/day, for two weeks. Before administration of TA-0201 (week 0), exogenous high ET-1 (0.1 nmol/kg i.v.) increased mean blood pressure ( 20 4.8 mmHg, n 15). The pressor effect of high ET-1 was not suppressed ( 16 3.8 mmHg, n 5) by administration of 0.05 mg/kg/day TA-0201 for two weeks, whereas TA-0201 administration of 0.1 mg/kg/day and 0.5 mg/kg/day (n 5, each) did not induce the pressor effect of high ET-1 ( 2 4.2 mmHg at 0.1 mg/kg/day; 0 2.6 mmHg in 0.5 mg/kg/day, p 0.01 vs. week 0). TA-0201 (0.5 mg/kg/ day) decreased basal mean blood pressure after two weeks ( 8 3.6 mmHg, n 5, p 0.01 vs. before TA-0201 administration), whereas 0.1 and 0.05 mg/kg/ day TA-0201 did not change; therefore, we considered that 0.1 mg/kg/day TA-0201 is suitable in this study.
Plasma Assays
Before each epicardial LAD endothelial denudation, arterial blood samples from the cannulated arterial sheath introducer and venous blood samples from the coronary sinus were taken to measure the plasma concentration of ET-1 and ascorbyl free radical (AFR), a marker of oxygen free radical trapped by ascorbic acid 11) . Plasma ET-1 was determined by radioimmunoassay using an endothelin-1 [I 125 ] assay system (Amersham, UK) 12) . AFR was measured by the electron spin resonance (ESR) method 11) . Signal intensities (SI) were used as indicators of AFR concentrations. Plasma ascorbic acid was measured by HPLC/ electrochemical detector methods 13) .
Detection of Superoxide
We performed fluorescence microtopography stained with dihydroethidium to detect superoxide produced in the myocardium perfused by denuded LAD, as described previously 14) . Frozen samples were cut into 30 m-thick sections and placed on slide glasses. Dihydroethidium (5 mol/L) was applied to each tissue section. The slides were incubated in a light-protected humidified chamber at 37 for 20 minutes. The dihydroethidium image was obtained by an OLYMPUS laser scanning confocal imaging system (OLYMPUS Optical Co. Ltd., Tokyo, Japan) with a 585-nm long-pass filter. Generation of reactive oxygen species (ROS) was demonstrated by red fluorescence labeling.
Histology and Endothelial Nitric Oxide Synthase (eNOS) Protein Expression
After the 8-week procedure, coronary arteries of pigs were flushed with 10 mL saline containing 10 g/kg nitroglycerin and 10 g/kg adenosine after the hearts were excised. The hearts were then perfused with 10% formaldehyde at a pressure of 100 mmHg and fixed in 10% formaldehyde for a few days; thereafter, the hearts were cut transversely from base to apex serially at 1 cm intervals. The tissue was embedded in paraffin, sectioned (5 m thick) and in-situ immunoenzymatic staining of eNOS was performed in the LAD microvessels (downstream of endothelial denuded vessels) and the corresponding vessels. The primary antibodies used were rabbit polyclonal antihuman endothelial cell constitutive nitric oxide synthase IgG (2.0 g/mL; Santa Cruz Biotech) 9) . We counted human CD- 31 , indicating intimal thickening, were calculated. As previously reported 9) , lumen diameter from 50 m to 150 m and the corresponding external elastic membrane cross-sectional area to lumen cross-sectional area, which is the index of medial thickening in various sizes of microvessels, were measured from 6 to 30 microvessels. This analysis enabled us to evaluate vascular remodeling in different sizes of microvessels. In these assessments, samples from each pig were observed, and the percentage of eNOS-positive cells and the ratio of intima area to media area were calculated and then averaged. In addition, the epicardial denuded portion of LAD was used to estimate eNOS protein expression. Western blotting of cell extracts was performed as described previously 15) . Briefly, aliquots containing 20 g of proteins were subjected to SDS/polyacrylamide gel electrophoresis. We used a mouse monoclonal antibody to human eNOS (Transduction Laboratories, Lexington, KY) diluted 1:1000. The signals from immunoreactive bands were visualized with an Amersham ECL TM System (Amersham, Bucks, UK).
Statistical Analysis
Data are expressed as the mean SEM. Statistical analysis was performed by ANOVA followed by Scheffe's post-hoc test. Student's t -test was used to compare paired or unpaired data. Differences in intimal thickening and the percent of eNOS-positive stained cells in coronary arteries were evaluated by one-way ANOVA followed by Fisher's exact test for multiple comparisons. A value of 0.05 was considered significant.
Results
Body Weight, Baseline Pressure-Rate Product, Coronary Vascular Resistance, and Coronary Artery Diameter in Repeatedly Denuded Portions
The body weight of pigs increased over 8 weeks (Control group, 18 2 kg increase; ED group, 17 3 kg increase; ED ETA group, 18 3 kg increase). The baseline mean aortic pressure-rate product and LAD vascular resistance did not change in any of the groups throughout the experimental period [pressure-rate product at week 8 (mmHg/
Coronary Blood Flow in Response to ACh
In the Control group, LAD blood flow in response to ACh did not significantly change throughout the experiment. In the ED group, decreases of LAD blood flow in response to ACh were induced by repeated LAD endothelial denudation after 2 W and ACh-induced LAD blood flow fell to zero at 8 W Table 1 ). The duration of zero LAD blood flow was 46 4.8 seconds; however, ACh did not change the diameter of the epicardial coronary artery even at this zero flow [Fig. 1A, 1B(b) ], indicating coronary microvascular spasm. In the ED ETA group, the decreases of LAD blood flow induced by ACh were prevented throughout the experimental period [ Fig. 1B(a) ], and the ECG ST-segment did not change ( Table 1) .
Endothelin-1 Concentration in Coronary Sinus
In ED and ED ETA groups, the plasma concentration of ET-1 in coronary sinus blood was increased by repeated endothelial denudation (ED group: 0W; 5.4 0.6 pg/mL, 8W; 7.4 0.8 pg/mL, p 0.05, ED ETA group: 0W; 5.6 0.4 pg/mL, 8W; 7.6 0.6 pg/mL, p 0.05) ( Table 2) .
ROS Generation
In the ED group, baseline levels of AFR in the coronary sinus were increased by epicardial endothelial denudation (0W; 26.2 3.6 SI, 8W; 69.5 6.4 SI, p 0.01); however, the increase of AFR caused by endothelial denudation was prevented by ETA antagonist (0W; 27.5 2.3 SI, 8W; 32.4 7.2 SI, p 0.01) (Fig. 2) . Plasma concentration of ascorbic acid in peripheral arterial blood did not change in the three groups throughout the experimental period (Table 3) . Fig. 3 demonstrated the prominent generation of superoxide in the myocardial area perfused by LAD in the ED group compared with the Control group. Chronic treatment with ETA antagonist suppressed superoxide production.
Furthermore,
eNOS Expression in Denuded Sites and Downstream Microvessels
Western blot analysis revealed that eNOS expression in repeated denuded portions was decreased in the ED group compared with the Control group and that chronic administration of ETA antagonist attenuated the downregulation of eNOS expression induced by repeated endothelial denudation (Fig. 4a, upper  panel) and as a result eNOS expression increased from 28 4.5% to 75 5.6% (p 0.01) (Fig. 4a, (Fig. 4b, lower panel) .
Effect of ET-A Antagonist on Vascular Remodeling
In the Control group, the intima to media ratio of epicardial coronary artery was 0.04 0.02 (n 10). In LAD denuded portions in the ED group, the intima to media ratio increased to 0.80 0.07 (n 8, p 0.01, vs. Control group), whereas chronic administration of ETA antagonist reduced the ratio to 0.07 0.03 (n 8, vs. ED group, p 0.01) ( Table 4) . A representative photomicrograph of each group is shown in Fig. 5 , upper panel. In downstream small vessels with 50 m up to 150 m diameter of the LAD perfusion area, medial thickening was observed in the ED group (2.75 0.21, n 15) compared with the Control group (1.93 0.06, n 18, p 0.05, vs. ED group). In the ED ETA group, medial thickening was also significantly ameliorated (2.08 0.47, n 16, p 0.05, vs. ED group) (Fig. 5, lower panel) .
Discussion
ET-1 is a potent vasoconstrictive peptide that is primarily produced by endothelial cells as well as inflammatory macrophages and activated smooth muscle cells [16] [17] [18] [19] . We show that chronic administration of ETA antagonist prevents coronary microvascular con- In the present study, repeated endothelial denudation markedly reduced LAD blood flow to zero with no change in the diameter of LAD in response to a small dose of ACh, especially in the later experimental period in our porcine model, suggesting that this may be a novel model of coronary microvascular spasm. Our immunohistochemistry demonstrated the downregulation of eNOS expression in downstream microvessels of denuded LAD compared with the control; thus, it is likely that epicardial endothelial injury induced microvascular endothelial dysfunction. Moreover, repeated endothelial denudation induced ROS generation in the myocardial area perfused by denuded LAD, indicating that epicardial endothelial injury caused ROS generation in the downstream perfused area. It has been reported that ROS causes ET-1 upregulation 20) and ET-1 promotes ROS generation, mediated via NAD(P)H oxidase in cardiomyocytes, endothelial cells, smooth muscle cells and macrophages 17, 18, 21) . In our model, ROS generated by endothelial denudation may induce ET-1 production and promote further ROS generation. In fact, it was clearly demonstrated in the present study that ETA antagonist prevented ACh induced coronary microvascular spasm, as well as the increase of plasma AFR levels. Since plasma ET-1 levels are still high even after treatment with ETA antagonist, the message via endothelin type Table 1 . week 0; before LAD endothelial denudation week 8: 2 weeks after 4 LAD endothelial denudations taken from coronary sinus in three groups at 0 and 8 weeks.
Baseline levels of AFR at 8 W markedly increased in ED group compared with Control group; however, ETA antagonist prevented the increase of AFR caused by endothelial denudation. Data are expressed as the mean SEM. p 0.01 vs. 0 W in the same group. p 0.01 vs. Control group in the same week. p 0.01 vs. ED group in the same week. Tables 1 and 2. A receptor seems to be most important for inducing coronary microvascular spasm and also for determining ROS generation. Although ROS seemed to be generated by several tissues, including cardiomyocytes, microvessels and fibroblasts, in our model, further study is needed to identify the cell sources of ROS generation in response to endothelial denudation in this porcine model.
Our previous study have shown that blockade of ROS generation by vitamin C and gluthatione attenu- ated coronary microvascular spasm in the same model, suggesting the involvement of ROS in coronary microvascular spasm induced by endothelial denudation 22) . A recent human study also suggested a role of ROS in the pathogenesis of epicardial coronary artery spasm 23) . These data suggest that not only the increase of ET-1 but also ROS generation play a crucial role in coronary microvascular spasm following ACh stimulation. It is well known that ROS downregulates NO production [24] [25] [26] and NO impairment has been shown to be involved in coronary vasospasm [27] [28] [29] . Our previous report first showed that repeated endothelial denudation induced the downregulation of eNOS expression in the coronary microvessels in this model 22) . Also, the downregulation of eNOS expression in downstream microvessels of denuded LAD was demonstrated in this study. The present study suggests that endothelial denudation-mediated ROS may impair microvascular endothelial dysfunction in association with ET-1 production and chronic administration of ETA antagonist suppressed ET-1-induced coronary microvascular spasm since ETA antagonist markedly attenuated the downregulation of eNOS in the downstream microvessels of denuded LAD.
Kinlay et al. reported that intracoronary administration of ETA antagonist is effective for the active constriction of human atherosclerotic coronary arteries 30) and Ruschitzka et al. showed that ETA antagonist attenuates vascular dysfunction including eNOS impairment 31) ; however, no report has shown the effect of ETA antagonist on coronary microvascular spasm and this is the first to describe that chronic administration of ETA antagonist is effective to prevent coronary microvascular spasm. In conclusion, the present study provides evidence using a porcine coro- Left panels, Control group; Center panels, ED group; Right panels, ED ETA group. In the ED group, thickening of media and increased perivascular fibrosis are shown. Scale bars indicate 100 m. Images in upper and lower panels were taken at 50 and 200 magnification, respectively. nary microvasclar spasm model that coronary microvascular spasm attack mediates ET-1. Further study is needed to assess whether the strategy of its blockade may be useful for treatment in a clinical setting.
Study Limitations
From our previous report 32) , it is likely that microvessels may more easily acquire heightened sensitivity to various pathological stimuli than the large coronary artery and that global spontaneous coronary spasm, including downstream microvessels, might finally occur in this model. As the downstream coronary microvessel is never directly damaged during our experimental procedure, abnormal stimuli produced in the epicardial coronary artery may induce microvascular spasm. In this model, it is difficult to collect microvessels to quantitative analyze eNOS protein expression by Western blotting or phosphorylation of eNOS because the amount of protein is too small; however, pretreatment with intravenous N--nitro-Larginine methyl ester enhanced LAD microvascular spasm in this model 9) . Therefore, it seems likely that the attenuated expression of eNOS has an important role in inducing microvascular spasm; however, further study is needed to clarify the mechanism of microvascular spasm and the relationship to eNOS.
The pathologic processes involved in microvascular spasm are unclear and whether this phenomenon represents a distinct clinical entity is also unknown. Recently, we developed an animal model with characteristics of microvascular spasm that occur spontaneously 32) . In this model, the reduction in flow to intracoronary acetylcholine is greatly augmented and the dilation to serotonin is converted to constriction. No change in LAD diameter was associated with these flow reductions. We believe that this model raises the possibility that microvascular spasm is simply a diffuse increase in arteriolar sensitivity to vasoconstrictor stimuli, possibly owing to endothelial dysfunction, rather than true focal spasm of coronary microvessels. It is known that endothelial dysfunction may occur after brief episodes of ischemia, so-called endothelial stunning, which is more prominent in the coronary microcirculation 33) . Microvascular spasm may be the clinical manifestation of endothelial stunning; however, further study is required to clarify microvascular spasm.
